Quote from VigiServe Admin on February 10, 2026, 1:06 PM

In Saint Lucia, Pharmacovigilance is overseen by the Ministry of Health, Wellness and Elderly Affairs (Pharmacy Services Unit). The system is minimalistic and relies heavily on the regional CARPHA (Caribbean Public Health Agency) framework and the VigiCarib reporting platform.

1. Clinical Safety (Clinical Trials)

Clinical trials are rare. When they occur, they require Ministry of Health approval and adherence to international norms.

• Expedited Reporting: Sponsors are expected to report Suspected Unexpected Serious Adverse Reactions (SUSARs). While not codified in national law, the practice aligns with CARPHA/international (ICH E2A) standards:

  • Fatal or Life-Threatening: Within 7 calendar days.

  • Other Serious Unexpected: Within 15 calendar days.

• Submission: Reports are submitted directly to the Ministry or CARPHA via forms or email.

2. Post-Marketing Pharmacovigilance

There are no strict local obligations for Marketing Authorization Holders.

• Personnel & Infrastructure:

  • No Local QPPV: There is no requirement for a local Qualified Person for Pharmacovigilance residing in Saint Lucia.

  • No PSMF Mandate: Marketing Authorization Holders (MAHs) are not required to register or maintain a Pharmacovigilance System Master File.

• Incident Reporting (ICSRs):

  • Enforcement: Voluntary/Spontaneous.

  • Timelines: "Prompt" reporting is expected for serious cases (generally interpreted as 15 days).

• Risk & Periodic Reporting:

  • PSURs: Not routinely mandatory.

  • RMPs: Not required.

Summary of Requirements

Component	Requirement in Saint Lucia
Regulatory Authority	MoH (Ministry of Health)
Regional Framework	CARPHA / VigiCarib
Local QPPV / PSMF	Not required
Safety Reporting	Spontaneous; "Prompt" reporting
Clinical Reporting	SUSARs (7/15 days - International practice)
Regional Alignment	WHO / CARPHA
Submission Language	English